Compare IDEXX Laboratories, Inc. (IDXX) vs MasterCard Inc (MA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs MasterCard Inc — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while MasterCard Inc trades at $589.14 (market cap $503.50B). The key difference: MasterCard Inc is far larger — about 12.5× IDEXX Laboratories, Inc.'s market cap, and MasterCard Inc pays a 0.61% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and MasterCard Inc for 134 Days on average.
| IDXX | MA | |
|---|---|---|
Market Cap | $40.43B | $503.50B |
Volume | 692,164 | 3,390,859 |
Sector | Health | Financials |
52-Week High | $766.68 | $599.86 |
52-Week Low | $504.70 | $471.55 |
Typical Hold Time | 46 Days | 134 Days |
Enterprise Value | $41.32B | $516.53B |
Dividend Yield | — | 0.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $513.14, up 1.28% with strong fundamentals including 25.03% net income margin and 74.21% ROE. The stock shows bearish technical signals but maintains consistent earnings beats and analyst consensus of $665 price target. Recent acquisition of CoVetAI expands AI capabilities in veterinary workflow intelligence, supporting long-term growth framework.
Outlook remains positive with revenue growth accelerating to $4.3B in 2025 and projected $4.6B in 2026. Key risks include foreign exchange headwinds and weaker U.S. veterinary visits. The 56.5% buy rating from analysts suggests continued confidence in the company's diagnostic innovation pipeline and recurring revenue economics.
Mastercard (MA) trades at $574.76, up 0.82% today, with a bullish technical signal and strong fundamental performance. Revenue grew to $32.79B in 2025, with a net income margin of 46.34%. The stock is supported by consistent earnings beats and a robust analyst consensus of 80% buy ratings. Recent institutional buying activity and positive media coverage highlight investor confidence.
The outlook remains positive given Mastercard's high profitability, expanding digital payment initiatives, and upward earnings trajectory. Key risks include competitive disruption from new payment technologies and regulatory scrutiny. With a consensus price target of $666.67, the stock offers potential upside, but investors should monitor execution against growth targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About MasterCard Inc
Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.
Read more on MA →
